~~<i id='41AFCF66D8'><strike id='41AFCF66D8'><tt id='41AFCF66D8'><pre id='41AFCF66D8'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：knowledge 2025-09-27 15:17:42 Page View：112

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Travel bans should be based on evidence, not politics or fear
Next article： Activists slam private health insurers over coverage restrictions

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

1:37FacebookCEOMarkZuckerbergspeaksabout"NewsTab"atthePaleyCenter,Oct.25,2019,inNewYork.MarkLennihan

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

1:35PoliceblocktherentalhomewherefourUniversityofIdahostudentswerestabbedtodeathinNovember2022,inMos

WSS

knowledge

knowledge

focus

explore

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene